Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
$1.32
$0.01(0.54%)
At close: 4:00 PM EST
$1.32
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.40 - $2.27
Previous CloseN/A
Volume579.15K
Average Volume (3M)670.12K
Market Cap
$78.18M
Enterprise Value-$40.95M
Total Cash (Recent Filing)$60.63M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Mar 05, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding53,551,132
10 Day Avg. Volume555,214
30 Day Avg. Volume670,121
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap-0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$3.00Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Aspen-Breast trial starts enrollment this quarter with an interim readout planned, using centralized CD47 testing and ctDNA-based HER2 confirmation.
Innovative Drug DesignEvorpacept’s differentiation is attributed to its fully 'dead-Fc' design, which eliminates macrophage-activating effector function—the flaw that caused every prior CD47 program to have limiting on-target hematologic toxicity.
Market PotentialALX believes there are ~20K addressable patients with CD47-high 2L+ HER2+ breast cancer in the US, EU5.
Bears Say
Financial StandingALX Oncology reported no revenues and a net loss, which aligns with consensus expectations but reflects financial challenges.
Industry ChallengesThe murky history of the CD47 targeting class (although ALX is taking a fundamentally different approach to the target).
Limited Cash ReservesYears of Cash Left ~1.5.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.40 and its highest was $2.27 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $78.18M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Mar 05, 2026 which is in 92 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Nov 07, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.043.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.36.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 53,551,132 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went up 16.949%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
ALX Oncology Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (127.27% Upside)
$3.00 (127.27% Upside)
Hedge Fund Trend
Increased
By 795.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $99.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.66%
12-Months-Change
Fundamentals
Return on Equity
-118.95%
Trailing 12-Months
Asset Growth
-55.59%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc. (ALXO) is a clinical-stage immuno-oncology company focusing on the development of therapies designed to enhance the immune system's ability to eliminate cancer. The company's main product candidate, evorpacept (also known as ALX148), is a CD47-blocking therapeutic aimed at preventing cancer cells from evading the immune system. ALX Oncology operates within the biotechnology and pharmaceutical sectors, targeting various solid tumors and hematologic malignancies.
ALXO Company Deck
ALXO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong clinical results for evorpacept and promising progress for ALX2004. The company is well-funded and advancing its pipeline with optimism. However, there are challenges related to market positioning and historical concerns with ADCs that need addressing.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$3.00
▲(127.27% Upside)
Technical Analysis
Adverum Biotechnologies
―
InflaRx
―
Quince Therapeutics
―
Adagene
―
Context Therapeutics
―
Ownership Overview
2.95% Insiders
3.43% Mutual Funds
31.77% Other Institutional Investors
59.41% Public Companies and
Individual Investors